Asset profile
Emraclidine
Small molecule
Evidence outlook · lead readout
NCT05227703 · Schizophrenia
The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found.
NCT05227703: Participants were randomly assigned to emraclidine 15 mg, emraclidine 30 mg, or matching placebo and were double-blinded, with 130–131 participants per group. The primary clinical endpoint was not met: the Week 6 PANSS comparison was nonsignificant for both 15 mg versus placebo (p=0.2925) and 30 mg versus placebo (p=0.3914).
Also in development:Alzheimer's Disease · Phase 1
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2028 (1)
February 2028 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.